{"entity": "journal", "iuid": "ddc822f3119d4732a24b88320cc414de", "timestamp": "2026-08-22T06:51:01.715Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/ESC%20Heart%20Fail.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/ESC%20Heart%20Fail"}}, "title": "ESC Heart Fail", "issn": "2055-5822", "issn-l": null, "publications_count": 3, "publications": [{"entity": "publication", "iuid": "8a97d56f7294464db12d8e6596df1c68", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8a97d56f7294464db12d8e6596df1c68.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8a97d56f7294464db12d8e6596df1c68"}}, "title": "Iron deficiency in new onset heart failure: association with clinical factors and quality of life.", "authors": [{"family": "Cabrera", "given": "Carin Corovic", "initials": "CC"}, {"family": "Ekstr\u00f6m", "given": "Mattias", "initials": "M"}, {"family": "Tornvall", "given": "Per", "initials": "P"}, {"family": "L\u00f6fstr\u00f6m", "given": "Ulrika", "initials": "U"}, {"family": "Frisk", "given": "Christoffer", "initials": "C"}, {"family": "Linde", "given": "Cecilia", "initials": "C"}, {"family": "Hage", "given": "Camilla", "initials": "C"}, {"family": "Persson", "given": "Hans", "initials": "H"}, {"family": "Eriksson", "given": "Maria J", "initials": "MJ"}, {"family": "Wall\u00e9n", "given": "H\u00e5kan", "initials": "H"}, {"family": "Persson", "given": "Bengt", "initials": "B"}, {"family": "Lyng\u00e5", "given": "Patrik", "initials": "P"}], "type": "journal article", "published": "2024-10-00", "journal": {"title": "ESC Heart Fail", "issn": "2055-5822", "volume": "11", "issue": "5", "pages": "2661-2671", "issn-l": null}, "abstract": "The prevalence of iron deficiency (ID) in newly diagnosed heart failure (HF) and the progression of ID in patients after initiation of HF therapy are unknown. We aimed to describe the natural trajectory of ID in patients with new onset HF during the first year after HF diagnosis, assessing associations between ID, clinical factors, and quality of life (QoL).\n\nA prospective cohort of patients with new onset HF in hospitals or outpatient clinics at five major hospitals in Stockholm, Sweden, during 2015-2018 were analysed with clinical assessment, electrocardiogram, blood samples including iron levels, Minnesota living with heart failure questionnaire (MLHFQ), and echocardiogram at baseline and after 12 months. Of 547 patients with new-onset HF, 482 (88%) had complete iron data at baseline. Median age was 70 years (interquartile range 61-77) and 311 (65%) were men; 55% of patients had ejection fraction (EF) \u2264 40%, 19% had EF 41-49%, and 26% had HF with preserved EF (HFpEF) [Correction added on 26 June 2024, after first online publication: The 'Mean age was 70 years' has been corrected to 'Median age was 70 years' in this version.]. At baseline, 163 patients (34%) had ID defined as ferritin <100 \u03bcg/L or ferritin 100-299 \u03bcg/L and transferrin saturation <20%. After 12 months of follow-up, 119 (32%) had ID of the 368 patients who had complete iron data both at baseline and after 12 months and did not receive intravenous (i.v.) iron during follow-up. During the first year after HF diagnosis, 19% had persistent ID, 13% developed ID, 11% resolved ID, and 57% never had ID, consequently 24% changed their classification. Anaemia at baseline was the strongest independent predictor of ID 1 year after diagnosis [odds ratio (OR) 3.91, 95% confidence interval (CI) 1.88-8.13, P < 0.001], followed by HF hospitalization (OR 2.21, 95% CI 1.24-3.95, P < 0.01), female sex (OR 2.04, 95% CI 1.25-3.32, P < 0.01), HFpEF (OR 1.96, 95% CI 1.13-3.39, P < 0.05), and diabetes mellitus (OR 1.92, 95% CI 1.06-3.48, P < 0.05). ID was associated with low QoL at baseline (MLHFQ score mean difference 7.4 points, 95% CI 3.1-11.7, P < 0.001), but not at follow-up.\n\nAbout one third of patients with new onset HF had ID both at the time of HF diagnosis and after 1 year, though a quarter of the patients changed their ID status. Patients with anaemia, HF hospitalization, female gender, HFpEF, or diabetes mellitus at baseline were more likely to have ID after 1 year implying that these should be carefully screened for ID to find those in need of i.v. iron treatment.", "doi": "10.1002/ehf2.14849", "pmid": "38803153", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11424290"}], "notes": [], "created": "2026-08-20T06:32:21.868Z", "modified": "2026-08-20T06:32:21.905Z"}, {"entity": "publication", "iuid": "2bca71d71ae34457ada31047c7b83c7c", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/2bca71d71ae34457ada31047c7b83c7c.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/2bca71d71ae34457ada31047c7b83c7c"}}, "title": "Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study.", "authors": [{"family": "Linde", "given": "Cecilia", "initials": "C"}, {"family": "Ekstr\u00f6m", "given": "Mattias", "initials": "M"}, {"family": "Eriksson", "given": "Maria J", "initials": "MJ"}, {"family": "Maret", "given": "Eva", "initials": "E"}, {"family": "Wall\u00e9n", "given": "H\u00e5kan", "initials": "H"}, {"family": "Lyng\u00e5", "given": "Patrik", "initials": "P"}, {"family": "Wed\u00e9n", "given": "Ulla", "initials": "U"}, {"family": "Cabrera", "given": "Carin", "initials": "C"}, {"family": "L\u00f6fstr\u00f6m", "given": "Ulrika", "initials": "U"}, {"family": "Stenudd", "given": "Jenny", "initials": "J"}, {"family": "Lund", "given": "Lars H", "initials": "LH"}, {"family": "Persson", "given": "Bengt", "initials": "B"}, {"family": "Persson", "given": "Hans", "initials": "H"}, {"family": "Hage", "given": "Camilla", "initials": "C"}, {"family": "Stockholm County/Karolinska Institutet 4D heart failure investigators", "given": "", "initials": ""}], "type": "journal article", "published": "2022-08-00", "journal": {"title": "ESC Heart Fail", "issn": "2055-5822", "volume": "9", "issue": "4", "pages": "2125-2138", "issn-l": null}, "abstract": "We present the baseline characteristics of the PREFERS Stockholm epidemiological study on the natural history and course of new onset heart failure (HF) aiming to improve phenotyping focusing on HF with preserved left ventricular ejection fraction (HFpEF) pathophysiology.\n\nNew onset HF patients diagnosed in hospital or at outpatient HF clinics were included at five Stockholm hospitals 2015-2018 and characterized by N-terminal pro brain natriuretic peptide (NT-proBNP), biomarkers, echocardiography, and cardiac magnetic resonance imaging (subset). HFpEF [left ventricular ejection fraction (LVEF) \u2265 50%] was compared with HF with mildly reduced LVEF (HFmrEF; LVEF 41-49%) and with HF with reduced LVEF (HFrEF; LVEF \u2264 40%). We included 547 patients whereof HFpEF (n = 137; 25%), HFmrEF (n = 61; 11%), and HFrEF (n = 349; 64%). HFpEF patients were older (76; 70-81 years; median; interquartile range) than HFrEF (67; 58-74; P < 0.001), more often women (49% vs. 30%; P < 0.001), and had significantly higher comorbidity burden. They more often had atrial fibrillation, hypertension, and renal dysfunction. NT-proBNP was lower in HFpEF (896; 462-1645 ng/L) than in HFrEF (1160; 563-2370; P = 0.005). In HFpEF, left ventricular (LV) diameters and volumes were smaller (P < 0.001) and septal and posterior wall thickness and relative wall thickness higher (P < 0.001). E/\u00e9 \u2265 14 was present in 26% of HFpEF vs. 32% of HFrEF (P = 0.017) and left atrial volume index > 34 mL/m2 in 57% vs. 61% (P = 0.040). HFmrEF patients were intermediary between HFpEF and HFrEF for LV mass, LV volumes, and RV volumes but had the highest proportion of left ventricular hypertrophy and the lowest proportion of elevated E/\u00e9.\n\nPhenotype data in new onset HF patients recruited in a broad clinical setting showed that 25% had HFpEF, were older, more often women, and had greater comorbidity burden. PREFERS is well suited to further explore biomarker and imaging components of HFpEF pathophysiology and may contribute to the emerging knowledge of HF epidemiology.\n\nClinicaltrials.gov identifier: NCT03671122.", "doi": "10.1002/ehf2.13922", "pmid": "35403374", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9288754"}, {"db": "ClinicalTrials.gov", "key": "NCT03671122"}], "notes": [], "created": "2026-08-20T06:32:17.632Z", "modified": "2026-08-20T06:32:17.685Z"}, {"entity": "publication", "iuid": "cca0cf321b43495f9c727bf99f555889", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/cca0cf321b43495f9c727bf99f555889.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/cca0cf321b43495f9c727bf99f555889"}}, "title": "The metabolites urobilin and sphingomyelin (30:1) are associated with incident heart failure in the general population.", "authors": [{"family": "Stenemo", "given": "Markus", "initials": "M"}, {"family": "Ganna", "given": "Andrea", "initials": "A"}, {"family": "Salihovic", "given": "Samira", "initials": "S"}, {"family": "Nowak", "given": "Christoph", "initials": "C"}, {"family": "Sundstr\u00f6m", "given": "Johan", "initials": "J"}, {"family": "Giedraitis", "given": "Vilmantas", "initials": "V"}, {"family": "Broeckling", "given": "Corey D", "initials": "CD"}, {"family": "Prenni", "given": "Jessica E", "initials": "JE"}, {"family": "Svensson", "given": "Per", "initials": "P"}, {"family": "Magnusson", "given": "Patrik K E", "initials": "PKE"}, {"family": "Lind", "given": "Lars", "initials": "L"}, {"family": "Ingelsson", "given": "Erik", "initials": "E"}, {"family": "\u00c4rnl\u00f6v", "given": "Johan", "initials": "J"}, {"family": "Fall", "given": "Tove", "initials": "T"}], "type": "journal article", "published": "2019-08-00", "journal": {"title": "ESC Heart Fail", "issn": "2055-5822", "volume": "6", "issue": "4", "pages": "764-773", "issn-l": null}, "abstract": "We aimed to investigate whether metabolomic profiling of blood can lead to novel insights into heart failure pathogenesis or improved risk prediction.\n\nMass spectrometry-based metabolomic profiling was performed in plasma or serum samples from three community-based cohorts without heart failure at baseline (total n = 3924; 341 incident heart failure events; median follow-up ranging from 4.6 to 13.9 years). Cox proportional hazard models were applied to assess the association of each of the 206 identified metabolites with incident heart failure in the discovery cohorts Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) (n = 920) and Uppsala Longitudinal Study of Adult Men (ULSAM) (n = 1121). Replication was undertaken in the independent cohort TwinGene (n = 1797). We also assessed whether metabolites could improve the prediction of heart failure beyond established risk factors (age, sex, body mass index, low-density and high-density lipoprotein cholesterol, triglycerides, lipid medication, diabetes, systolic and diastolic blood pressure, blood pressure medication, glomerular filtration rate, smoking status, and myocardial infarction prior to or during follow-up). Higher circulating urobilin and lower sphingomyelin (30:1) were associated with incident heart failure in age-adjusted and sex-adjusted models in the discovery and replication sample. The hazard ratio for urobilin in the replication cohort was estimated to 1.29 per standard deviation unit, 95% confidence interval (CI 1.03-1.63), and for sphingomyelin (30:1) to 0.72 (95% CI 0.58-0.89). Results remained similar after further adjustment for established heart failure risk factors in meta-analyses of all three cohorts. Urobilin concentrations were inversely associated with left ventricular ejection fraction at baseline in the PIVUS cohort (\u03b2 = -0.70, 95% CI -1.03 to -0.38). No major improvement in risk prediction was observed when adding the top 2 metabolites (C-index 0.787, 95% CI 0.752-0.823) or nine Lasso-selected metabolites (0.790, 95% CI 0.754-0.826) to a modified Atherosclerosis Risk in Communities heart failure risk score model (0.780, 95% CI 0.745-0.816).\n\nOur metabolomic profiling of three community-based cohorts study identified associations of circulating levels of the haem breakdown product urobilin, and sphingomyelin (30:1), a cell membrane component involved in signal transduction and apoptosis, with incident heart failure.", "doi": "10.1002/ehf2.12453", "pmid": "31148414", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6676274"}], "notes": [], "created": "2026-08-20T06:32:15.669Z", "modified": "2026-08-20T06:32:15.738Z"}], "created": "2026-08-20T06:32:15.698Z", "modified": "2026-08-20T06:32:15.698Z"}